No profile data available.
Unicycive Therapeutics, Inc. (UNCY) is a healthcare company in the urinary system treatment drugs industry, based in Mountain View, United States, with about 21 full-time employees.
It reported revenue of $0 for fiscal year 2024, down 100.0% from fiscal year 2023, and net income of -$37.82 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $112.59 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States.
Unicycive Therapeutics reported $0 in revenue for fiscal year 2024, down 100.0% from $675,000 in fiscal year 2023. In Q3 2025 revenue was $0.
$112.59 million as of October 9, 2026.
Listed companies of a similar size in the same industry (urinary system treatment drugs) include ProKidney Corp. (PROK), Akebia Therapeutics, Inc. (AKBA), Jyong Biotech Ltd. (MENS), Cyclerion Therapeutics, Inc. (CYCN).